TheDman / iStockphoto.com
7 June 2018Americas
Astellas accuses Cipla of infringing overactive bladder patent
Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Asia-Pacific
31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Generics
8 March 2022 Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.
Editor's picks
Editor's picks
Asia-Pacific
31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Generics
8 March 2022 Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.
Asia-Pacific
31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Generics
8 March 2022 Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.